Neoadjuvant, Adjuvant, or Both? The Debate in NSCLC Rages On Neoadjuvant, Adjuvant, or Both? The Debate in NSCLC Rages On
The question of whether to give upfront immunochemotherapy in resectable non –small cell lung cancer, wait until after surgery, or give both remains a hot topic of debate.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 27, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
' We Finally Made It': Amivantamab Comes of Age in NSCLC'We Finally Made It': Amivantamab Comes of Age in NSCLC
Data from three trials with the amivantamab in advanced EGFR-mutant NSCLC have yielded"exciting" results with experts hailing the drug as standard of care in various settings.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 26, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
New Options Challenge Standard Treatments in EGFR-Mutant NSCLC
(MedPage Today) -- MADRID -- Two positive phase III trials involving amivantamab (Rybrevant)-based regimens introduced new first- and second-line options in EGFR-mutant non-small cell lung cancer (NSCLC), though toxicity with the combination... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 25, 2023 Category: Hematology Source Type: news
ALK Inhibitor Outperforms Adjuvant Chemotherapy for Resected Lung Cancer
(MedPage Today) -- MADRID -- Disease-free survival (DFS) in resectable ALK-positive non-small cell lung cancer (NSCLC) improved by 76% with adjuvant alectinib (Alecensa) compared with chemotherapy, according to a randomized trial.
Across disease... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 24, 2023 Category: Hematology Source Type: news
Targeting KRAS in NSCLC: Recent Progress and New Approaches
(MedPage Today) -- MedPage Today brought together three expert leaders for a virtual roundtable discussion on lung cancer: Moderator Roy Herbst, MD, PhD, is joined by Anne Chiang, MD, PhD, and So Yeon Kim, MD, all from the Yale Cancer Center in... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 23, 2023 Category: Hematology Source Type: news
New First-Line Standard for Lung Cancers With EGFR Exon 20 Insertions
(MedPage Today) -- MADRID -- Amivantamab (Rybrevant) confirmed its clinical benefit in advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions, and in doing so has established a new first-line standard for this patient population... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 23, 2023 Category: Hematology Source Type: news
RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLC
(MedPage Today) -- MADRID -- First-line treatment with the RET inhibitor selpercatinib (Retevmo) achieved superior outcomes in both medullary thyroid cancer (MTC) and advanced non-small cell lung cancer (NSCLC), according to results from two... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 23, 2023 Category: Hematology Source Type: news
ALK Inhibitor Alectinib Shows DFS Benefit in Early NSCLC ALK Inhibitor Alectinib Shows DFS Benefit in Early NSCLC
Interim findings from the ALINA trial show improved DFS with alectinib in the adjuvant setting vs chemotherapy in resected stage IB-IIIA NSCLC. But will early DFS results extend to overall survival?Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 22, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
ESMO: Jemperli appears to show survival edge over Keytruda
Last year, a first-of-its-kind head-to-head clinical trial between two PD-1 inhibitors went in GSK’s favor. Now, the British pharma has some new patient survival data to celebrate. Compared with Merck’s market-leading Keytruda, GSK’s Jemperli demonstrated a 25% lower risk of death in patients with…#pd1 #gsk #merck #keytruda #nsclc #heshamabdullah #fiercepharma #jemperli #pdl1negative #pdl1 (Source: Reuters: Health)
Source: Reuters: Health - October 21, 2023 Category: Consumer Health News Source Type: news
Perioperative Nivolumab Improves EFS in Resectable NSCLC Perioperative Nivolumab Improves EFS in Resectable NSCLC
Interim findings from CheckMate 77T show an overall improvement in event-free survival with perioperative nivolumab vs neoadjuvant nivolumab plus chemotherapy only.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 21, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
ESMO Abstract Leak Reveals Promising NSCLC Therapies from BMS, BeiGene, J & J, Mirati
Pictured: Illustration of a tumor in the lungs/iStock, Mohammed Haneefa Nizamudeen Following an embargo breach, the organizers of the upcoming European Society for Medical Oncology Congress 2023 on Tuesday made available all late-breaking abstracts to be presented during the meeting. The decision…#nsclc #bristolmyerssquibb #opdivo #johnsonjohnson #astrazeneca #tagrisso #biospace #spain #bms #checkmate (Source: Reuters: Health)
Source: Reuters: Health - October 19, 2023 Category: Consumer Health News Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products
Basel, 19 October 2023Groupsales grow by 1%1at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products,Group salesincrease by 9%Pharmaceuticals Division sales grow by 9%, driven by continued high demand for newer medicinesDiagnostics Division ’s base businessincreases by 7%;overall divisional sales are down 18% due to a surge in demand for COVID-19 tests in 2022Highlightsin the third quarter of 2023:EU approval ofEvrysdifor babies under two months old with spinal muscular atrophyFirst approval of subcutaneous form of cancer immunotherapyTecen...
Source: Roche Media News - October 19, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products
Groupsales grow by 1%1at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products,Group salesincrease by 9%Pharmaceuticals Division sales grow by 9%, driven by continued high demand for newer medicinesDiagnostics Division ’s base businessincreases by 7%;overall divisional sales are down 18% due to a surge in demand for COVID-19 tests in 2022Highlightsin the third quarter of 2023:EU approval ofEvrysdifor babies under two months old with spinal muscular atrophyFirst approval of subcutaneous form of cancer immunotherapyTecentriqPositive phase III...
Source: Roche Investor Update - October 19, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Alecensa reduces the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage non-small cell lung cancer
These Phase III data are the first and only to show an improvement in disease-free survival in early-stage resected ALK-positive non-small cell lung cancer (NSCLC)With about one in two people with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy,1 more effective treatment options are urgently needed to provide the best chance for cure2Data are being presented as a late-breaking oral during the ESMO 2023 Presidential SymposiumBasel, 18 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the primary analysis of the Phase III ALINA study demonstratin...
Source: Roche Media News - October 18, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Alecensa reduces the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage non-small cell lung cancer
These Phase III data are the first and only to show an improvement in disease-free survival in early-stage resected ALK-positive non-small cell lung cancer (NSCLC)With about one in two people with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy,1 more effective treatment options are urgently needed to provide the best chance for cure2Data are being presented as a late-breaking oral during the ESMO 2023 Presidential SymposiumBasel, 18 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the primary analysis of the Phase III ALINA study demonstratin...
Source: Roche Investor Update - October 18, 2023 Category: Pharmaceuticals Source Type: news
